Eravacycline · Xerava

What is Eravacycline?

Eravacycline is a tetracycline class antibacterial drug indicated for treatment of complicated intra-abdominal infections caused by susceptible bacteria including Escherichia coli, Klebsiella pneumoniae, Enterococcus species, Staphylococcus aureus, and other gram-negative and gram-positive organisms in patients 18 years or older.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Xerava

Drug type

Small molecule

Therapy area

Infectious disease

Developer

Tetraphase Pharms

In trials of

INVA

FDA status

Approved as Xerava (August 27, 2018), NDA211109 · FDA label

✅ FDA-approved uses

• Complicated intra-abdominal infections

From the indications section of the FDA label (version of Mar 31, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Complicated Intra-abdominal Infections (cIAI)

Sources

• FDA label (DailyMed)
• FDA label Xerava (2025-03-31), indications
• ClinicalTrials.gov NCT06794541

Updated Oct 3, 2026.